- Home
- MCRB vs RPID Comparison
MCRB vs RPID Comparison
Compare MCRB & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- RPID
- Stock Information
- Founded
- MCRB 2010
- RPID 2006
- Country
- MCRB United States
- RPID United States
- Employees
- MCRB N/A
- RPID 163
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- RPID Medical Specialities
- Sector
- MCRB Health Care
- RPID Health Care
- Exchange
- MCRB Nasdaq
- RPID Nasdaq
- Market Cap
- MCRB 144.6M
- RPID 167.6M
- IPO Year
- MCRB 2015
- RPID 2021
- Fundamental
- Price
- MCRB $20.47
- RPID $3.71
- Analyst Decision
- MCRB Hold
- RPID Strong Buy
- Analyst Count
- MCRB 4
- RPID 2
- Target Price
- MCRB $14.33
- RPID $8.00
- AVG Volume (30 Days)
- MCRB 227.9K
- RPID 78.8K
- Earning Date
- MCRB 11-12-2025
- RPID 10-31-2025
- Dividend Yield
- MCRB N/A
- RPID N/A
- EPS Growth
- MCRB N/A
- RPID N/A
- EPS
- MCRB 10.22
- RPID N/A
- Revenue
- MCRB N/A
- RPID $30,289,000.00
- Revenue This Year
- MCRB N/A
- RPID $16.63
- Revenue Next Year
- MCRB N/A
- RPID $21.98
- P/E Ratio
- MCRB $2.05
- RPID N/A
- Revenue Growth
- MCRB N/A
- RPID 22.57
- 52 Week Low
- MCRB $6.53
- RPID $0.83
- 52 Week High
- MCRB $24.67
- RPID $4.50
- Technical
- Relative Strength Index (RSI)
- MCRB 60.09
- RPID 66.03
- Support Level
- MCRB $19.14
- RPID $3.45
- Resistance Level
- MCRB $21.97
- RPID $3.90
- Average True Range (ATR)
- MCRB 1.52
- RPID 0.27
- MACD
- MCRB 0.22
- RPID 0.07
- Stochastic Oscillator
- MCRB 80.36
- RPID 79.47
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About RPID Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.